Claire Boulard
Overview
Explore the profile of Claire Boulard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calabrese L, Cinotti E, DOnghia M, Cartocci A, Rubegni P, Maccari F, et al.
Acta Derm Venereol
. 2025 Mar;
105:adv42275.
PMID: 40077977
Tralokinumab is a monoclonal antibody selectively targeting IL-13, approved for moderate-to-severe atopic dermatitis (AD), for which real-world data are scarce. This prospective, observational, multicentric study aimed to assess the long-term...
2.
Pollyn-Millot C, Maccari F, Perrot J, Reguiai Z, Boulard C, Becherel P, et al.
Acta Derm Venereol
. 2024 Sep;
104():adv40420.
PMID: 39248293
Atopic dermatitis (AD) is the most common chronic inflammatory dermatitis in developed countries, and has a major impact on those affected. Little is known about AD in elderly patients. This...
3.
Becherel P, Reguiai Z, Fougerousse A, Perrot J, Begon E, Thomas-Beaulieu D, et al.
Dermatology
. 2024 Jul;
240(5-6):702-712.
PMID: 39019015
Introduction: Chronic inflammatory dermatoses (CIDs) can significantly affect patients' lives. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) cohort was initiated to quantify the impact and disease evolution of four...
4.
Reguiai Z, Becherel P, Perrot J, Boulard C, Fougerousse A, Begon E, et al.
J Eur Acad Dermatol Venereol
. 2024 Jul;
38(11):2149-2155.
PMID: 39015045
Background: Clinical trials and real-life data have reported an increased incidence of conjunctivitis in patients treated with dupilumab for their atopic dermatitis (AD). Although mostly mild in severity, in some...
5.
Bocquel S, Soria A, Raison-Peyron N, Badaoui A, Marcant P, Bara C, et al.
J Am Acad Dermatol
. 2023 Oct;
90(3):512-520.
PMID: 37871801
Background: Limited and conflicting data have been reported on the impact of dupilumab (DUPI) on patch test (PT) results and its efficacy against allergic contact dermatitis (ACD). Objective: This study...
6.
Reguiai Z, Becherel P, Perrot J, Fougerousse A, Begon E, Poreaux C, et al.
Acta Derm Venereol
. 2023 Oct;
103:adv14153.
PMID: 37800349
The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of...
7.
Amsler E, Assier H, Soria A, Bara C, Ferrier le Bouedec M, Barbaud A, et al.
Contact Dermatitis
. 2022 Apr;
87(2):170-175.
PMID: 35383393
Background And Objectives: The repeated open application test (ROAT) is an adjuvant investigation measure to patch testing in the diagnosis of allergic contact dermatitis. ESCD recommends a 15 days duration...
8.
Beaumont C, Darrigade A, Barbaud A, Collet E, Raison-Peyron N, Bourrain J, et al.
Contact Dermatitis
. 2022 Feb;
87(1):62-70.
PMID: 35213760
Background: An aqueous antiseptic containing "chlorhexidine digluconate/benzalkonium chloride/benzyl alcohol" (CBB) is widely used in France. The only previous documented study dealing with allergic contact dermatitis (ACD) to this antiseptic is...
9.
Phan C, Beneton N, Delaunay J, Reguiai Z, Boulard C, Fougerousse A, et al.
Acta Derm Venereol
. 2020 Oct;
100(18):adv00316.
PMID: 33111960
Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A...
10.
Tedbirt B, Carvalho P, Boulard C, Tetart F, Deschamps-Huvier A, Chenal P, et al.
Int J Low Extrem Wounds
. 2020 Oct;
22(1):135-138.
PMID: 33076722
Eccrine syringofibroadenoma (ESFA) is a rare adnexal tumor deriving from the acrosyringeal portion of the eccrine duct. Five subtypes of ESFA were described including a reactive form. Reactive ESFAs are...